Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Covington
Moodys
Healthtrust
Fish and Richardson
Federal Trade Commission
Citi
Boehringer Ingelheim
Daiichi Sankyo

Generated: June 21, 2018

DrugPatentWatch Database Preview

SOMATULINE DEPOT Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Somatuline Depot patents expire, and when can generic versions of Somatuline Depot launch?

Somatuline Depot is a drug marketed by Ipsen Pharma and is included in one NDA. There is one patent protecting this drug.

This drug has seventy-one patent family members in seventeen countries.

The generic ingredient in SOMATULINE DEPOT is lanreotide acetate. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the lanreotide acetate profile page.
Summary for SOMATULINE DEPOT
International Patents:71
US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 5
Clinical Trials: 23
DailyMed Link:SOMATULINE DEPOT at DailyMed
Drug patent expirations by year for SOMATULINE DEPOT
Pharmacology for SOMATULINE DEPOT

US Patents and Regulatory Information for SOMATULINE DEPOT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ipsen Pharma SOMATULINE DEPOT lanreotide acetate SOLUTION;SUBCUTANEOUS 022074-001 Aug 30, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Ipsen Pharma SOMATULINE DEPOT lanreotide acetate SOLUTION;SUBCUTANEOUS 022074-002 Aug 30, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Ipsen Pharma SOMATULINE DEPOT lanreotide acetate SOLUTION;SUBCUTANEOUS 022074-001 Aug 30, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Ipsen Pharma SOMATULINE DEPOT lanreotide acetate SOLUTION;SUBCUTANEOUS 022074-003 Aug 30, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for SOMATULINE DEPOT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,837,276 Apparatus for the delivery of elongate solid drug compositions ➤ Sign Up
6,306,420 Methods and apparatus for the delivery of solid drug compositions ➤ Sign Up
5,582,591 Delivery of solid drug compositions ➤ Sign Up
6,142,972 Method and apparatus for the delivery of elongate solid drug compositions ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for SOMATULINE DEPOT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
037 Luxembourg ➤ Sign Up 91037, EXPIRES: 20160511
2002 00032 Denmark ➤ Sign Up
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Boehringer Ingelheim
Medtronic
Baxter
Johnson and Johnson
McKesson
Queensland Health
Farmers Insurance
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.